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Background: To report our initial clinical experience of helical tomotherapy (HT) in the treatment of locally
advanced oropharynx and inoperable oral cavity cancer.
Methods: Between February 2008 and January 2011, 24 consecutive patients, 15 with oropharyngeal cancer and 9
with oral cavity cancer were treated with exclusive radiotherapy or concomitant chemoradiotherapy. Simultaneous
integrated boost (SIB) in 30 fractions scheme was prescribed to all patients, using Helical Tomotherapy. Doses
administered to primary tumor, oropharynx/oral cavity and positive lymph-nodes and negative lymph-nodes were
66–67.5 Gy, 60–63 Gy and 54 Gy, respectively.
Results: Complete response rate for the oropharynx and the oral cavity group was 86.7% and 77.8%, respectively.
The 1 and 2-year Overall Survival (OS) and Disease Free Survival (DFS) rate for the oropharynx group was 92.9%,
85.1%, 92.9% and 77.4% respectively. For the oral cavity group, 1 and 2-year OS and DFS rates were 55.6%, 55.6%,
75% and 75%, respectively. No patient developed grade ≥3 mucositis, dysphagia or dermatitis. The maximum late-toxicity
grade observed was 2, for all the variables examined.
Conclusions: HT appears to achieve encouraging clinical outcomes in terms of response, survival and toxicity rates.
Keywords: Helical tomotherapy, Oropharyngeal cancer, Oral cavity cancer, Intensity-modulated radiotherapy,
Concurrent chemoradiationIntroduction
Carcinomas of the oropharynx and oral cavity are two of
the most common types of head and neck squamous cell
carcinoma (HNSCC), which is the sixth leading cancer
by incidence worldwide [1]. HNSCCs are strongly asso-
ciated with certain lifestyle risk factors such as tobacco
smoking and alcohol consumption [2,3]. Oropharyngeal
infection by oncogenic type-16 human papillomavirus
(HPV) has been also associated with oropharyngeal squa-
mous cell carcinoma [4].
Although survival rates for HNSCC are improving,
locoregional control remains suboptimal, especially in pa-
tients with advanced-stage disease; in this setting, treatment* Correspondence: vdonato@scamilloforlanini.rm.it
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reproduction in any medium, provided the orshould involve a multidisciplinary team approach (head
and neck surgeon, medical oncologist, radiation oncolo-
gist). Regarding oral cavity carcinoma, surgery has been
and still remains the mainstay of treatment for resectable
tumors, reserving radiation therapy for the advanced
stages. On the other hand, chemoradiotherapy or radio-
therapy can be used as exclusive treatment, either for ini-
tial or advanced-stage oropharyngeal cancer, in order to
preserve functional anatomy.
During the last decade, radiation oncology has witnessed
an explosion in innovation of treatment modalities: inten-
sity modulated radiotherapy (IMRT) allows to deliver a
high radiation dose to the tumor, with improved target
conformality and surrounding healthy tissue sparing, in
comparison with three-dimensional (3D) plans [5-7].
Helical tomotherapy (HT) is an innovative radiother-
apy technique, which integrates linear accelerator andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient characteristics














Base of tongue 4 (16.7%)
Soft palate 2 (8.3%)
Retromolar trigone 4 (16.7%)
Floor of mouth 3 (12.5%)
Oral tongue 2 (8.3%)
Pathology n %
Squamous cell carcinoma 24 (100%)
Abbreviations: ECOG PS Eastern Cooperative Oncology Group Performance Status.
Table 2 Tumor stage
Disease stage n %
Stage III 4 (16.7%)
Stage IVA 20 (83.3%)
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IMRT in an helical pattern, thanks to a continuously ro-
tating gantry. The integrated image-guidance system pro-
vides daily 3D imaging of the tumor, achieving precise
irradiation, and therefore decreased toxicity to healthy tis-
sue, with possible treatment adaption (Image Guided
Radiotherapy or IGRT) [8,9].
A tomotherapy Hi-Art® system was introduced into
clinical routine at the Department of Radiation Oncology,
San Camillo-Forlanini Hospital, Rome, Italy, in January
2008. This article reports our initial clinical experience of
HT, in the treatment of patients with locally advanced
oropharynx and inoperable oral cavity carcinoma, in terms
of response, acute and late toxicity rates.
Materials and methods
Patient and tumor characteristics
Between February 2008 and September 2011, a total of
105 head and neck cancer patients (60 men and 55 women,
median age 62 years old, range 33–86) were treated with
HT, either definitively or postoperatively, at San Camillo-
Forlanini Hospital of Rome. The present study group con-
sists of 24 consecutive patients, 15 with oropharyngeal
cancer (tonsil, n = 9, base of tongue, n = 4, soft palate, n = 2)
and 9 with oral cavity cancer (retromolar trigone, n = 4,
floor of mouth, n = 3, oral tongue, n = 2), treated with ex-
clusive radiotherapy or concomitant chemoradiotherapy,
from February 2008 to January 2011 (Table 1). There were
15 males and 9 females with a median age of 58 years old
(range 45–85) and an Eastern Cooperative Oncology
Group Performance Status (ECOG PS) as follows: ECOG
1, n = 4 patients; ECOG 2, n = 18 patients; ECOG ≥ 3,
n = 2 patients. The staging evaluation included: clinical
examination, fiberoptic endoscopic evaluation, Positron
Emission Tomography (PET)/ Magnetic Resonance Im-
aging (MRI) scans of the head and neck region, chest
X-ray, complete blood counts, liver and renal function
tests and dental evaluation.
Concerning clinical stage, 20 patients (83.3%) had a IVA
stage disease and 4 patients (16.7%) a III stage, according
to the 7th Edition of the American Joint Committee on
Cancer (AJCC). Twenty one patients had an advanced pri-
mary tumor stage (T3, n = 41.6%, T4a, n = 45.8%) and
were node positive (Table 2). All patients provided written
informed consent.
Radiotherapy treatment planning
Patients were immobilized in the supine position, with
the neck hyper-extended, using a head rest and custom
thermoplastic mold, achieving head, neck and shoulders
immobilization. During the simulation process, CT images
indexed every 5-mm were obtained with a CT scanner for
treatment planning. Target volumes and normal structures
were contoured on a Pinnacle® treatment planning systemand MRI/PET images were fused with the CT images, in
order to delineate the gross tumor volume (GTV). This
latter was defined as the volume containing the visible on
imaging and/or clinically detectable tumor, while the
GTV-node, as any lymph nodes over 10 mm in short axis
dimension or smaller nodes with necrotic centres or
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obtained adding 3 mm margins to clinical target volume
(CTV). Brainstem was contoured as an organ at risk
(OAR) with a maximum dose of 54 Gy. Spinal cord was
outlined with a 3 mm isocentric margin, also (maximum
dose 45 Gy). Other critical organs included: optic chi-
asm and optic nerve (maximum dose 45 Gy), mandible
(maximum dose 70 Gy), inner ear (mean dose <50 Gy)
and both parotid glands. These latter are responsible for
60% to 65% of the saliva produced and xerostomia is a
major acute and late side effect that can have a signifi-
cant negative impact on a patient’s quality of life; in
order to limit this kind of toxicity, particular attention
was paid during treatment planning, achieving a mean
dose <26 Gy.
Radiotherapy was delivered once daily, five days a week,
using a tomotherapy Hi-Art® machine. Megavoltage CT
acquisitions were performed before treatment in all pa-
tients for setup verification. Simultaneous integrated
boost (SIB) in 30 fractions scheme was prescribed to all
patients.
Patients treated with exclusive radiotherapy received a
dose of 67.5 Gy in 2.25 Gy daily fractions for tumor and
63 Gy in 2.1 Gy daily fractions for oropharynx/oral cav-
ity and positive lymph nodes. Lower doses were used for
patients treated with concomitant chemotherapy: 66 Gy
in 2.2 Gy daily fractions for tumor and 60 Gy in 2 Gy
daily fractions for oropharynx/oral cavity and positive
lymph nodes. Negative lymph nodes were irradiated with
equal dose for both groups: 54 Gy in 1.8 Gy daily
fractions.
Chemotherapy
Of the 24 patients, 15 (oropharyngeal carcinoma, n = 10,
oral cavity carcinoma, n = 5) received concomitant
platinum-based chemotherapy. Patients over 80 years of
age or those with a poor ECOG performance status and/
or affected by comorbid conditions, received only radio-
therapy. Subsite of tumor distribution of chemotherapy-
treated patients was as follows: tonsil, n = 7, base of
tongue, n = 3, retromolar trigone, n = 2, floor of mouth,
n = 2, oral tongue, n = 1. Chemotherapy (either carboplatin
100mg/m [2] or cisplatin 80 mg/m [2]) was given intraven-
ously every 3 weeks in an outpatient setting. Taking into
account the fact that we used an hypofractionated re-
gime, a lower dosage of chemotherapy (cisplatin 80 mg/mq
instead of 100 mg/q) was administrated in order to con-
tain toxicity.
Clinical assessment
Patients were assessed at least weekly during radiother-
apy by a radiation oncologist and every 2 weeks by an
otolaryngologist for adverse effects. Toxicity was scored
according to the Common Terminology Criteria forAdverse Effects, version 4.0. Acute-toxicity assessment,
performed during the radiotherapy treatment, included
mucositis, dysphagia and dermatitis. Late-toxicity assess-
ment, performed during the follow-up visits, included
xerostomia, pain, trismus, fibrosis and neck edema.
Response at treatment was evaluated 3 months after
the completion of radiotherapy, on the basis of a clinical
examination and CT or MRI scans. Complete response
was defined as the disappearance of tumor and lymph
node involvement, while partial response as the decrease
in the multiplication product of the two largest diame-
ters of tumor and/or positive lymph nodes by at least
50%.
After completion of treatment, follow-up visit, performed
once a month the first 6 months, every 3 months the first
2 years and every 6 months thereafter, included: physical
examination, MRI/PET scans and fiberoptic endoscopic
examination. The median follow-up period was 24 months
(range 3–53).
Statistical methods
The statistical method used was the Kaplan- Meier sur-
vival analysis. For the calculation of Disease Free Survival,
the event was defined as a) reccurrence of disease or b)
cancer-related death. Death not related to cancer was not
considered as event.
Results
Twenty-three out of 24 patients (95.8%) received the
complete course of planned radiotherapy. Only one patient
did not complete the radiation therapy course because of
clinical deterioration, requiring recovery. No patient
required the insertion of nasogastric or percutaneous
endoscopic gastrostomy (PEG) tube for nutritional sup-
port during radiotherapy.
Treatment outcome
From the analysis of oropharynx cancer patients, a
complete response was observed in 13 out of 15 patients
(86.7%). The 1 and 2-year overall survival (OS) rate was
92.9% and 85.1%, respectively, while the 1 and 2-year
disease-free survival (DFS) rate was 92.9% and 77.4%, re-
spectively (Figure 1). One patient died of disease pro-
gression, 2 of concurrent disease (myocardial infarction,
pulmonary embolism), while a fourth patient, who had a
partial response, died 17 months after the completion of
radiotherapy due to heart failure. There was no evidence
of distant metastases. Relapse of disease has been observed
only in one patient (subsite: base of tongue, stage IVA),
40 months after the end of radiotherapy.
From the analysis of oral cancer patients, a complete
response was observed in 7 out of 9 patients (77.8%). The
1 and 2-year OS rate was 55.6%, while the 1 and 2-year
DFS rate was 75% (Figure 2). Only one patient presented
Figure 1 Overall survival and disease-free survival of the oropharynx group.
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after the completion of radiotherapy. Two patients died of
disease progression and 2 of concurrent disease (liver
disease, intestinal perforation).
Acute and late toxicity
Concerning acute-toxicity, grade 1 and grade 2 mucositis
was observed in 12.5% and 87.5 % of patients, respect-
ively. As for dysphagia, 70.8% of patients developed
grade 2 toxicity, while the rest of them (29.2%) grade 1.
Regarding dermatitis, grade 1 toxicity was observed in
54.2% of patients and grade 2 in the rest of them
(45.8%). No patient developed grade ≥3 mucositis, dyspha-
gia or dermatitis (Table 3). Late-toxicity was evaluated in
18 patients, as in 2 patients were clinical assessment was
not feasible and 4 died shortly (within 6 months) after the
completion of treatment. The maximum grade late-
toxicity observed was grade 2 for all the adverse effects ex-
amined; many patients, did not develop toxicity at all, for
certain variables (Table 4). Median time of evaluation of
xerostomia was 24 months. Mild xerostomia (grade 1)
was the most frequent late-toxicity effect (11 patients,
61.1%). Six patients did not experience xerostomia at all,
while 1 patient complained grade 2 xerostomia. Regarding
pain symptom, 61.1% of patients did not experience pain,
while 4 of them (22.2%) experienced grade 1 and, 3Figure 2 Overall survival and disease-free survival of the oral cavity gpatients (16.7%) grade 2 pain. Trismus was absent in
77.8% of patients; only 4 patients (22.2%) developed
trismus, grade 1. Late fibrosis (grade 1) was present
in 10 patients (56.5%) and absent in the rest of them.
Only 7 patients (38.9%) developed neck edema (grade 1).Discussion
In the treatment of oropharyngeal/oral cavity carcinoma,
locoregional control is one of the most important goals
to achieve, as local recurrences are common and repre-
sent a frequent cause of death. Considering the natural
history of disease and the relatively low incidence of dis-
tant metastases, an effective local control could be trans-
lated in a higher possibility of cure. However, obtainment
of a satisfactory local control requires high radiation doses
to the target volume and, consequently, appropriate spar-
ing of surrounding normal tissue, in order to minimize
acute and late toxicity.
HT is an advanced IGRT technique that permits ac-
curate delivery of a high, conformal dose to the target
volume from a rotational gantry. Its additional option in
inverse planning optimization, results in a more uniform
dose to the tumor and a better avoidance of organs at
risk, thus, in a higher locoregional control probability
with decreased toxicity rates.roup.
Table 4 Late toxicity rates
Xerostomia n %
Absent 6 (33.3%)
Grade 1 11 (61.1%)
Grade 2 1 (5.6%)
Grade 3 0 (0%)
Grade 4 0 (0%)
Grade 5 0 (0%)
Fibrosis n %
Absent 10 (55.5%)
Grade 1 8 (44.5%)
Grade 2 0 (0%)
Grade 3 0 (0%)
Grade 4 0 (0%)
Grade 5 0 (0%)
Trismus n %
Absent 14 (77.8%)
Grade 1 4 (22.2%)
Grade 2 0 (0%)
Grade 3 0 (0%)
Pain n %
Absent 11 (61.1%)
Grade 1 4 (22.2%)
Grade 2 3 (16.7%)
Grade 3 0 (0%)
Neck edema n %
Absent 11 (61.1%)
Grade 1 7 (38.9%)
Grade 2 0 (0%)
Grade 3 0 (0%)
Table 3 Acute toxicity rates
Mucositis n %
Grade 1 3 (12.5%)
Grade 2 21 (87.5%)
Grade 3 0 (0%)
Grade 4 0 (0%)
Grade 5 0 (0%)
Dysphagia n %
Grade 1 7 (29.2%)
Grade 2 17 (70.8%)
Grade 3 0 (0%)
Grade 4 0 (0%)
Grade 5 0 (0%)
Dermatitis n %
Grade 1 13 (54.2%)
Grade 2 11 (45.8%)
Grade 3 0 (0%)
Grade 4 0 (0%)
Grade 5 0 (0%)
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HT in the treatment of patients with locally advanced
oropharynx and inoperable oral cavity carcinoma, pro-
vided encouraging results in terms of response, survival
and toxicity rates.
The evidence of literature concerning IMRT for oro-
phanyngeal carcinoma, reports 2-year locoregional tumor
control rates of 90 to 98% for patient populations con-
sisting mainly of stage III–IV disease [10]. However, these
series contain both definitively and postoperatively treated
patients, and variable ratios of patients treated with con-
current chemoradiotherapy or radiotherapy alone. Chao
et al. [11] compared IMRT to conventional radiotherapy
techniques, in the treatment of oropharyngeal carcinoma
with definitive radiotherapy; they reported a 2-year loco-
regional control and DFS rate of 68% and 58% for the con-
ventional radiotherapy treated group, and 88% and 80%
rate for the IMRT treated group, respectively.
The M D Anderson Cancer Center (MDACC) experi-
ence in the treatment of oropharyngeal carcinoma with
definitive IMRT, reported a 4-year estimate of DFS, loco-
regional control and distant metastasis-free survival of
66%, 78% and 84%, respectively [12].
Shueng et al [13] published the preliminary results of
their experience of concurrent chemoradiotherapy for
oropharyngeal cancer using HT. Ten patients were treated
with concomitant chemoradiotherapy to doses of 70 Gy,
63 Gy and 56 Gy to the GTV, high-risk subclinical area
and low-risk subclinical area, respectively. The actuarial
OS, DFS, locoregional control and distant metastasis-free
survival rates at 18 months were 67%, 70%, 80% and 100%,respectively. No grade 3 toxicity for dermatitis and body
weight loss and only one instance of grade 3 mucositis
were noted.
Despite the clear efficacy of a combined-modality ap-
proach in locally advanced oral/oropharyngeal squamous
cell carcinoma, toxicity can be considerable [14]. Long-
term xerostomia is one of the most inconvenient side
effects. Sheng et al. [15] and Van Vulpen et al. [16]
analysed the advantages of sparing parotid glands, con-
cluding that HT could simultaneously reduce parotid
normal tissue complication probability and maintain
similar target dose homogeneity. The results obtained in
the present study confirmed this benefit regarding pa-
tient salivary function.
The Memorial Sloan-Kettering Cancer Center experi-
ence [17], in the treatment of oropharyngeal cancer
patients with IMRT, reported grade 3 dermatitis and
mucositis rates of 6% and 38%, respectively. Bhide et al
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cosa in patients receiving concomitant chemoradio-
therapy with IMRT technique for head and neck cancer,
using hypofractionated accelerated schemes of 2.17 Gy,
2.25 Gy and 2.4 Gy per fraction. Grade 3 dysphagia was
correlated with the length of pharyngeal mucosa receiv-
ing doses close to the prescription dose; its incidence
was lower and patients recovered earlier in case of greater
overall treatment time.
In our current study complete response, 2-year OS
and 2-year DFS rates in patients affected by locally ad-
vanced oropharyngeal carcinoma were 86.7%, 85.1% and
77.4%, respectively. In terms of clinical characteristics,
it’s necessary to underline that many patients presented
several negative features. In particular, there were 2 pa-
tients over age 80 years, 20 (83.3%) with an ECOG PS
≥2 and many suffering from important comorbid condi-
tions. This relates with the relative low number of pa-
tients not candidable to chemotherapy. In this report,
HPV status was not analyzed as it is not yet used to
guide treatment, except in the context of a clinical trial.
When available is valuable prognostically, being a favor-
able factor if positive. It could be hypothesized that part
of the favorable outcome in the oropharynx group can
be attributed to HPV positivity. Concerning clinical
stage, 20 patients (83.3%) were classified as stage IVA
and 21 (87.5%) had positive lymph nodes (with bilateral
involvement in 14, 58.3%). Compliance to the treatment
was excellent: all patients except one, completed planned
radiotherapy, while no patient presented the necessity to
feed by tube or PEG. Regarding acute effects, no grade
≥3 toxicity was registered; grade 2 mucositis, dysphagia
and dermatitis rates were 87.5%, 70.8% and 45.8%, re-
spectively. The overall absence of higher grade acute
mucositis could be due to daily MVCT of Helical To-
motherapy for set up verification, pharmacological ther-
apy administered for symptoms prevention and frequent
clinical checks. As for late toxicity, only one patient ex-
perienced grade 2 xerostomia.
The optimal management of oral cavity squamous cell
carcinoma typically requires surgical resection followed
by adjuvant radiotherapy or chemoradiotherapy, in the
setting of adverse pathologic features. Published IMRT
outcomes specific to this disease subsite are poor, al-
though post-operative IMRT is frequently used to treat
oral cavity cancers.
Hsieh CH et al. [19], who treated high-risk oral cavity car-
cinoma patients with HT in a postoperative setting, reported
2-year overall survival, disease-free survival, locoregional
control and distant metastasis-free rates of 94%, 84%, 92%
and 94%, respectively; grade 3 mucositis, dermatitis and
leucopenia rates were 42%, 5% and 5%, respectively.
In contrast, outcomes of locally advanced oral cavity
carcinoma patients treated with definitive radiotherapy,seem to be less successful, compared to adjuvant radio-
therapy treatment. Sher et al [20], reported a 2-year ac-
tuarial overall survival and local control rate of 85% and
91%, for adjuvant IMRT and 63% and 64%, for definitive
IMRT, respectively.
On the basis of this evidence, we adopted an hy-
pofractionated regimen, with a higher radiobiological
equivalent total dose to the primary tumor, in order to
improve local control and survival rates in patients
treated with exclusive radiotherapy. In our study,
complete response, 2-year OS and 2-year DFS rates in
inoperable oral cavity carcinoma, were 77.8%, 55.6% and
75%, respectively.
Conclusions
Concomitant radiochemotherapy or exclusive radiother-
apy represents an important therapeutic option and a
valid alternative to surgery, in patients affected by locally
advanced oropharynx and inoperable oral cavity carcin-
oma. Helical tomotherapy allows a high radiation dose
delivery to the target volume and therefore, an increased
probability of local control and improved survival rates.
Moreover, it’s capability to create highly conformal dose
distributions permits significant sparing of surrounding
organs at risk, decreasing the probability of acute and
late toxicity effects. The present study, provided encour-
aging results in terms of response, survival and toxicity
rates, however, a long-term follow-up and a larger num-
ber of patients are necessary, in order to confirm these
preliminary findings.
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